"BMS" の関連情報検索結果
The Bristol Myers Squibb Foundation - Bristol Myers Squibb
The Bristol Myers Squibb Foundation Bristol Myers Squibb
BMS secures subcutaneous Opdivo approval - FirstWord Pharma
BMS secures subcutaneous Opdivo approval FirstWord Pharma
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo - Reuters
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo Reuters
LGES, Qualcomm to collaborate on chip-based BMS - evertiq.com
LGES, Qualcomm to collaborate on chip-based BMS evertiq.com
Our impact - Bristol Myers Squibb
Our impact Bristol Myers Squibb
About us - Bristol Myers Squibb
About us Bristol Myers Squibb
With pair of trial wins in psoriatic arthritis, Bristol Myers Squibb looks to jump-start stagnant...
With pair of trial wins in psoriatic arthritis, Bristol Myers Squibb looks to jump-start stagnant Sotyktu FiercePharma
Global Inclusion & Diversity - Bristol Myers Squibb
Global Inclusion & Diversity Bristol Myers Squibb
Working at BMS - Bristol Myers Squibb
Working at BMS Bristol Myers Squibb
Our company: Industry leadership in BioPharma - Bristol Myers Squibb
Our company: Industry leadership in BioPharma Bristol Myers Squibb
BMS pays Leqembi originator $100M for next-gen preclinical Alzheimer's prospects - Fierce Biotech
BMS pays Leqembi originator $100M for next-gen preclinical Alzheimer's prospects Fierce Biotech
Families flock to BMS for yearly ice rink activities - WJHL-TV News Channel 11
Families flock to BMS for yearly ice rink activities WJHL-TV News Channel 11
Pharmaceutical business development - Bristol Myers Squibb
Pharmaceutical business development Bristol Myers Squibb
BMS keeps axing deals inked under old leadership, this time culling cell therapy pacts with Centu...
BMS keeps axing deals inked under old leadership, this time culling cell therapy pacts with Century, Immatics Fierce Biotech
Positive Phase III trials results with BMS’ Sotyktu - The Pharma Letter
Positive Phase III trials results with BMS’ Sotyktu The Pharma Letter
Bristol Myers Squibb taps AI Proteins in drug discovery collaboration worth up to $400M - Fierce ...
Bristol Myers Squibb taps AI Proteins in drug discovery collaboration worth up to $400M Fierce Biotech
Bristol Myers Squibb hands pink slips to 195 workers in New Jersey as cost-cutting effort rolls o...
Bristol Myers Squibb hands pink slips to 195 workers in New Jersey as cost-cutting effort rolls on FiercePharma
Bristol Myers Squibb latest drug company to sue HHS over 340B rebate model - Fierce healthcare
Bristol Myers Squibb latest drug company to sue HHS over 340B rebate model Fierce healthcare
Psoriasis around the world - Bristol Myers Squibb
Psoriasis around the world Bristol Myers Squibb
Areas of interest - Bristol Myers Squibb
Areas of interest Bristol Myers Squibb
Patients and caregivers - Bristol Myers Squibb
Patients and caregivers Bristol Myers Squibb
Our technologies - Bristol Myers Squibb
Our technologies Bristol Myers Squibb
BMS sees success in Phase III Sotyktu psoriatic arthritis trials - Yahoo Finance
BMS sees success in Phase III Sotyktu psoriatic arthritis trials Yahoo Finance
Michael R. McMullen - Bristol Myers Squibb
Michael R. McMullen Bristol Myers Squibb
People and business resource groups - Bristol Myers Squibb
People and business resource groups Bristol Myers Squibb
Independent research - Bristol Myers Squibb
Independent research Bristol Myers Squibb
Clinical trials & studies - Bristol Myers Squibb
Clinical trials & studies Bristol Myers Squibb
Global Inclusion & Diversity Report - Bristol Myers Squibb
Global Inclusion & Diversity Report Bristol Myers Squibb
Advancing Lymphoma Treatment with Protein Degradation - Bristol Myers Squibb
Advancing Lymphoma Treatment with Protein Degradation Bristol Myers Squibb
Get help paying for your medicines - Bristol Myers Squibb
Get help paying for your medicines Bristol Myers Squibb
Our research in immunology - Bristol Myers Squibb
Our research in immunology Bristol Myers Squibb
Post study drug access to BMS investigational medicinal products and approved products - Bristol ...
Post study drug access to BMS investigational medicinal products and approved products Bristol Myers Squibb
Become a business supplier - Bristol Myers Squibb
Become a business supplier Bristol Myers Squibb
BMS’ Cobenfy tipped to be top dog in growing schizophrenia space - FiercePharma
BMS’ Cobenfy tipped to be top dog in growing schizophrenia space FiercePharma
BMS stakes new ground for Sotyktu with Phase III wins in psoriatic arthritis - FirstWord Pharma
BMS stakes new ground for Sotyktu with Phase III wins in psoriatic arthritis FirstWord Pharma
Pre-approval access to investigational medicines - Bristol Myers Squibb
Pre-approval access to investigational medicines Bristol Myers Squibb
Transparency & reporting - Bristol Myers Squibb
Transparency & reporting Bristol Myers Squibb
Breaking barriers: SOGIIS data collection for improved health equity in clinical trials - Bristol...
Breaking barriers: SOGIIS data collection for improved health equity in clinical trials Bristol Myers Squibb
Immunology patient resources - Bristol Myers Squibb
Immunology patient resources Bristol Myers Squibb
BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal - BioSpace
BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal BioSpace
Worldwide locations - Bristol Myers Squibb
Worldwide locations Bristol Myers Squibb
Professional Service Automation Software for IT Professionals | Kaseya BMS - Kaseya
Professional Service Automation Software for IT Professionals | Kaseya BMS Kaseya
Global Patient Week 2024 - Bristol Myers Squibb
Global Patient Week 2024 Bristol Myers Squibb
BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma - OncLive
BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma OncLive
Our research in neuroscience - Bristol Myers Squibb
Our research in neuroscience Bristol Myers Squibb
Position biopharma industry key issues - Bristol Myers Squibb
Position biopharma industry key issues Bristol Myers Squibb
Our science - Bristol Myers Squibb
Our science Bristol Myers Squibb
Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC - OncLive
Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC OncLive
Highlights from our 2024 Climate Change Report - Bristol Myers Squibb
Highlights from our 2024 Climate Change Report Bristol Myers Squibb
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluatin...
Early innovation at BMS - Bristol Myers Squibb
Early innovation at BMS Bristol Myers Squibb
Translational medicine - Bristol Myers Squibb
Translational medicine Bristol Myers Squibb
Science Firsthand: The pathway to drug discovery - Bristol Myers Squibb
Science Firsthand: The pathway to drug discovery Bristol Myers Squibb
BMS' CAR-T cracks down on lupus, achieving sustained responses in phase 1 - Fierce Biotech
BMS' CAR-T cracks down on lupus, achieving sustained responses in phase 1 Fierce Biotech
Research and development areas of focus - Bristol Myers Squibb
Research and development areas of focus Bristol Myers Squibb
Science Firsthand: Translating the promise of cell therapy - Bristol Myers Squibb
Science Firsthand: Translating the promise of cell therapy Bristol Myers Squibb
Survivorship Today: Cancer survivor stories - Bristol Myers Squibb
Survivorship Today: Cancer survivor stories Bristol Myers Squibb
LGES launches its own battery management solution - www.electrive.com
LGES launches its own battery management solution www.electrive.com
Leveraging AI to enhance workplace innovation & efficiency - Bristol Myers Squibb
Leveraging AI to enhance workplace innovation & efficiency Bristol Myers Squibb
LG Energy Solution Announces Availability of Advanced Battery Management System Solutions for Aut...
LG Energy Solution Announces Availability of Advanced Battery Management System Solutions for Automotive Batteries News
Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments - BioSpace
Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments BioSpace
Our commitment towards transforming multiple myeloma treatment - Bristol Myers Squibb
Our commitment towards transforming multiple myeloma treatment Bristol Myers Squibb
A new era in Alzheimer's R&D: Dual approach to disease modification and symptom management - Bris...
A new era in Alzheimer's R&D: Dual approach to disease modification and symptom management Bristol Myers Squibb
ESMO 2024: CC-94676-PCA-001: Clinical Activity of BMS-986365, a Dual Androgen Receptor Ligand-Dir...
Advancing one’s growth and career development through a culture of inclusion and belonging - Bris...
Advancing one’s growth and career development through a culture of inclusion and belonging Bristol Myers Squibb
BMS Finds More Than 40% Survival Rate for Melanoma Combo Therapy at 10 Years - BioSpace
BMS Finds More Than 40% Survival Rate for Melanoma Combo Therapy at 10 Years BioSpace
Celebrating four years of patient engagement through PEER program - Bristol Myers Squibb
Celebrating four years of patient engagement through PEER program Bristol Myers Squibb
ASPIRE: Our commitment to address health inequities in low- and middle-income countries - Bristol...
ASPIRE: Our commitment to address health inequities in low- and middle-income countries Bristol Myers Squibb
BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipelin...
BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipeline Fierce Biotech
Commitment to safety and patients: Risk evaluation and mitigation strategies (REMS) - Bristol Mye...
Commitment to safety and patients: Risk evaluation and mitigation strategies (REMS) Bristol Myers Squibb
The evolution of lung cancer research - Bristol Myers Squibb
The evolution of lung cancer research Bristol Myers Squibb
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Th...
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma Bristol Myers Squibb - News
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $...
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research Bristol Myers Squibb - News
Q&A with Robert Plenge: What is Bristol Myers Squibb’s research strategy and where are we taking ...
Q&A with Robert Plenge: What is Bristol Myers Squibb’s research strategy and where are we taking it? Bristol Myers Squibb
Continuing Innovations on TYK2 Inhibition - Bristol Myers Squibb
Continuing Innovations on TYK2 Inhibition Bristol Myers Squibb
Reigniting Innovation in Neuropsychiatry - Bristol Myers Squibb
Reigniting Innovation in Neuropsychiatry Bristol Myers Squibb
How BMS employees champion STEM education & diversity - Bristol Myers Squibb
How BMS employees champion STEM education & diversity Bristol Myers Squibb
Developing tools to break the rules: Fostering innovation in cell therapy manufacturing - Bristol...
Developing tools to break the rules: Fostering innovation in cell therapy manufacturing Bristol Myers Squibb
BMS’ Opdivo Bests Pfizer’s Adcetris in Late-Stage Hodgkin’s Lymphoma Study - BioSpace
BMS’ Opdivo Bests Pfizer’s Adcetris in Late-Stage Hodgkin’s Lymphoma Study BioSpace
Driving innovative and inclusive practices at all levels of the BMS organization - Bristol Myers ...
Driving innovative and inclusive practices at all levels of the BMS organization Bristol Myers Squibb
Eisai Assumes Sole Responsibility for ADC After Collaboration With BMS Ends - BioSpace
Eisai Assumes Sole Responsibility for ADC After Collaboration With BMS Ends BioSpace
Celebrating 11 Years of C2C4C to Raise Funds for Cancer Research - Bristol Myers Squibb
Celebrating 11 Years of C2C4C to Raise Funds for Cancer Research Bristol Myers Squibb
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administrat...
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma Bristol Myers Squibb - News
The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia - BioSpace
The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia BioSpace
ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer fiel...
ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer field FiercePharma
BMS ditches TIGIT, walking away from $200M bet on Agenus bispecific - Fierce Biotech
BMS ditches TIGIT, walking away from $200M bet on Agenus bispecific Fierce Biotech
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapse...
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy Bristol Myers Squibb - News
Gene Editor Prime Medicine Signs BMS Cell Therapy Deal, Reprioritizes Pipeline - BioSpace
Gene Editor Prime Medicine Signs BMS Cell Therapy Deal, Reprioritizes Pipeline BioSpace
2024 Annual Meeting of Shareholders - Bristol Myers Squibb
2024 Annual Meeting of Shareholders Bristol Myers Squibb
As new drugs deliver, Bristol Myers CEO looks to 'further improve productivity and efficiency' - ...
As new drugs deliver, Bristol Myers CEO looks to 'further improve productivity and efficiency' FiercePharma
Unusual Liposome Image During Drug Research and Development - Bristol Myers Squibb
Unusual Liposome Image During Drug Research and Development Bristol Myers Squibb
BMS Backs Out of $1.5B Deal, Returns Rights to Agenus for Bispecific Antibody - BioSpace
BMS Backs Out of $1.5B Deal, Returns Rights to Agenus for Bispecific Antibody BioSpace
insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement ...
Bringing the science of cell therapy into autoimmune diseases - Bristol Myers Squibb
Bringing the science of cell therapy into autoimmune diseases Bristol Myers Squibb
Compañía Biofarmacéutica Global - Bristol Myers Squibb
Compañía Biofarmacéutica Global Bristol Myers Squibb
Chris Boerner, PhD - Bristol Myers Squibb
Chris Boerner, PhD Bristol Myers Squibb
Former BMS Professor and GeniPhys Founder Sees Continued Success in Development of Wound Manageme...
Former BMS Professor and GeniPhys Founder Sees Continued Success in Development of Wound Management Product Purdue University
Bristol Myers Squibb axes 79 more in New Jersey as $1.5B cost-reduction program rolls on - Fierce...
Bristol Myers Squibb axes 79 more in New Jersey as $1.5B cost-reduction program rolls on FiercePharma
Spreading eosinophilic esophagitis awareness and wellness in patients - Bristol Myers Squibb
Spreading eosinophilic esophagitis awareness and wellness in patients Bristol Myers Squibb
Annual reports - Bristol Myers Squibb
Annual reports Bristol Myers Squibb